Congressional analysis: Pay-for-delay ban would save US taxpayers $4.8B over 10 years
This article was originally published in SRA
Executive Summary
A report by the US Congressional Budget Office (CBO) has produced evidence that backs efforts by lawmakers to get legislation enacted that would ban patent settlements in which innovator drug makers pay generic manufacturers to delay the entrance into the marketplace of their cheaper generic versions1,2.